Multicenter Cohort Study of AAV in Hunan of China

Central South University

Status: Enrolling

Conditions: ANCA Associated Vasculitis

Treatments: Other: No Intervention

Study type: Observational

Funder types: Other

Identifiers

NCT05315141

202108374

Details and patient eligibility

About

This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.

Full description

The study is a multicenter prospective cohort study, aimed to explore the incidence of AAV and its progression and association with adverse consequences. The study will establish a baseline cohort of 500 AAV patients in Hunan province of China. The follow-up will be conducted for at least 5 years until death or starting renal replacement therapy or dropout. Their demographic characteristics, clinical data, laboratory and imaging examinations will be collected at baseline and every follow-up.

The baseline visit includes the following items: detailed demographics, medical and family history, medication history, health behaviors, physical activity, and anthropometric measures. The laboratory parameters of chemistry test. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection.

The principal clinical outcomes of the study can be broadly categorized as end stage renal disease and death. Death is further clarified as cardiac, infectious, renal, others, or unknown.

Enrollment: 500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent

Exclusion criteria

• Do not agree to sign informed consent

Trial design

500 participants in 5 patient groups

Xiangya Hospital

Treatment:

Other: No Intervention

The Second Xiangya Hospital

Treatment:

Other: No Intervention

The Third Xiangya Hospital

Treatment:

Other: No Intervention

Hunan Provincial People's Hospital

Treatment:

Other: No Intervention

Xiangtan Central Hospital

Treatment:

Other: No Intervention